Abstract
Cardiovascular disease represents the major cause of morbidity and mortality in patients with diabetes mellitus. Studies by us and others have implicated increased flux via aldose reductase (AR) as a key player in mediating diabetic complications, including cardiovascular complications. Data suggest that increased flux via AR in diabetics perpetuates increased injury after myocardial infarction, accelerates atherosclerotic lesion formation, and promotes restenosis via multiple mechanisms. Most importantly, studies have shown that increased generation of reactive oxygen species due to flux via AR has been a common feature in animal models of diabetic cardiovascular disease. Taken together, these considerations place AR in the center of biochemical and molecular stresses that characterize the cardiovascular complications of diabetes. Stopping AR-dependent signaling may hold the key to interrupting cycles of cellular perturbation and tissue damage in diabetic cardiovascular complications.
Keywords: Advanced glycation end products, Aldose reductase, Aldose reductase inhibitors, atherosclerosis, cardiovascular complications, Diabetes, hyperglycemia, ischemia reperfusion, Oxidative stress, Polyol pathway
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Volume: 10 Issue: 3
Author(s): Srinivasan Vedantham, Radha Ananthakrishnan, Ann Marie Schmidt and Ravichandran Ramasamy
Affiliation:
Keywords: Advanced glycation end products, Aldose reductase, Aldose reductase inhibitors, atherosclerosis, cardiovascular complications, Diabetes, hyperglycemia, ischemia reperfusion, Oxidative stress, Polyol pathway
Abstract: Cardiovascular disease represents the major cause of morbidity and mortality in patients with diabetes mellitus. Studies by us and others have implicated increased flux via aldose reductase (AR) as a key player in mediating diabetic complications, including cardiovascular complications. Data suggest that increased flux via AR in diabetics perpetuates increased injury after myocardial infarction, accelerates atherosclerotic lesion formation, and promotes restenosis via multiple mechanisms. Most importantly, studies have shown that increased generation of reactive oxygen species due to flux via AR has been a common feature in animal models of diabetic cardiovascular disease. Taken together, these considerations place AR in the center of biochemical and molecular stresses that characterize the cardiovascular complications of diabetes. Stopping AR-dependent signaling may hold the key to interrupting cycles of cellular perturbation and tissue damage in diabetic cardiovascular complications.
Export Options
About this article
Cite this article as:
Vedantham Srinivasan, Ananthakrishnan Radha, Marie Schmidt Ann and Ramasamy Ravichandran, Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (3) . https://dx.doi.org/10.2174/187152512802651097
DOI https://dx.doi.org/10.2174/187152512802651097 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B))
Current Pharmaceutical Design Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Targeting the Inflammatory Response in Healing Myocardial Infarcts
Current Medicinal Chemistry Evolution and Analysis of Heterogeneity in the Clinical Expression of Aortic Diseases Similar to Marfan’s Syndrome: Challenge and Art in Clinical Diagnosis
Current Rheumatology Reviews Covid-19: Pathophysiology; Mechanism of Transmission and Possible Molecular Drug Target for Management
Current Molecular Pharmacology The Effect of Licorice Drink on the Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Abnormal Insulin Signaling: Early Detection of Silent Coronary Artery Disease-Erectile Dysfunction?
Current Pharmaceutical Design Epidermolysis Bullosa: Pediatric Perspectives
Current Pediatric Reviews Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches
CNS & Neurological Disorders - Drug Targets Revised Genetic Classification of Limb Girdle Muscular Dystrophies
Current Molecular Medicine Contraception in Women with Medical Conditions
Current Women`s Health Reviews Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued)